Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

Cancer·2026

Same author

Bronchiolitis Post Introduction of RSV Immunoprophylaxis: Shifting Patterns in Pediatric Hospitalizations.

Clinical pediatrics·2026

Same author

A negative-hydrated constriction zone is revealed in the active state of the H<sub>v</sub>1 channel.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Direct targeting of C9ORF72 repeat RNA with fluorinated antisense oligonucleotides.

Nucleic acids research·2026

Same author

What I talk about when I talk about patient self-inflicted lung injury: an ultrastructural perspective.

Intensive care medicine experimental·2026

Same author

Minor groove tetrads: a potent and versatile capping interaction for i-motif structures.

Biophysical reviews·2026

Search research articles

Related Experiment Video

Updated: Jun 29, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Adoptive T cell therapy for solid tumors: current landscape and future challenges.

Víctor Albarrán¹, María San Román¹, Javier Pozas²

¹Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain.

Frontiers in Immunology

|March 29, 2024

Summary

This summary is machine-generated.

Adoptive cell therapy (ACT) shows promise for solid tumors, with tumor-infiltrating lymphocytes (TIL) therapy emerging as a key strategy. Challenges remain, but research is advancing T cell therapies for refractory cancers.

Keywords:

T cells TCR-modified cells TIL therapy adoptive cell therapy car-t immunotherapy melanoma

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

Related Experiment Videos

Last Updated: Jun 29, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

Area of Science:

Immunology
Oncology
Cell Therapy

Background:

Adoptive cell therapy (ACT) enhances T cell activity against tumors.
Chimeric antigen receptor (CAR) T-cell therapy shows success in hematologic cancers.
Solid tumors present challenges like heterogeneity and immunosuppression for ACT.

Purpose of the Study:

To review current knowledge on T cell therapy for solid tumors.
To summarize clinical results of ACT modalities in solid tumors.
To identify future research directions for T cell therapy in oncology.

Main Methods:

Review of existing literature on ACT for solid tumors.
Analysis of clinical outcomes for CAR T-cells, TCR-engineered T cells, and TIL therapy.
Discussion of challenges and future prospects of T cell therapy.

Main Results:

CAR T-cells face efficacy limitations in solid tumors due to tumor characteristics.
Tumor-infiltrating lymphocyte (TIL) therapy shows promise in specific cancers like melanoma.
Combination of TIL therapy with immune checkpoint inhibitors is a potential strategy.

Conclusions:

TIL therapy is a promising ACT modality for solid tumors, despite implementation challenges.
Further research is needed to overcome biological, logistical, and economic hurdles for widespread TIL therapy.
T cell therapy holds significant potential for treating patients with refractory solid tumors.